Chimeric antigen receptor (CAR) T cell therapy has emerged as a major advancement in cancer treatment. By engineering a patient’s T cells to recognize and eliminate cancer cells, this approach has transformed outcomes for certain blood cancers and is being actively investigated for solid tumors. However,